CADTH | Evidence Driven
CADTH | Evidence Driven

Caprelsa for Medullary Thyroid Cancer – Details

Details

Files
Generic Name:
Vandetanib
Project Status:
Complete
Therapeutic Area:
Medullary Thyroid Cancer
Manufacturer:
Sanofi Genzyme
Brand Name:
Caprelsa
Project Line:
Reimbursement Review
Project Number:
PC0090-000
NOC Status at Filing:
Post NOC
Strength:
100 mg and 300 mg tablets
Tumour Type:
Endocrine
Indications:
Medullary Thyroid Cancer
Funding Request:
For the treatment of symptomatic and/or progressive medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease
Sponsor:
Sanofi Genzyme
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Vandetanib (Caprelsa) Medullary Thyroid Cancer - pERC Final Recommendation Final Recommendation March 30, 2017 View PDF
Vandetanib (Caprelsa) Medullary Thyroid Cancer - Final Clinical Guidance Report Guidance Reports March 30, 2017 View PDF
Vandetanib (Caprelsa) Medullary Thyroid Cancer - Final Economic Guidance Report Guidance Reports March 30, 2017 View PDF
Vandetanib (Caprelsa) Medullary Thyroid Cancer - pERC Initial Recommendation Initial Recommendation February 2, 2017 View PDF
Vandetanib (Caprelsa) Medullary Thyroid Cancer - PAG Feedback on Initial Recommendation Feedback March 30, 2017 View PDF
Vandetanib (Caprelsa) Medullary Thyroid Cancer - Manufacturer Feedback on Initial Recommendation Feedback March 30, 2017 View PDF
Vandetanib (Caprelsa) Medullary Thyroid Cancer - Patient Advocacy Group Feedback on Initial Recommendation Feedback March 30, 2017 View PDF
Vandetanib (Caprelsa) Medullary Thyroid Cancer - Patient Advocacy Group COI Declarations COI Declarations March 30, 2017 View PDF
Vandetanib (Caprelsa) Medullary Thyroid Cancer - Clinician COI Declarations COI Declarations March 30, 2017 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 17, 2017